ASCO 2020 Bladder Cancer

REVIEW UroToday

Viewing 1-20 of 29 articles

ASCO 2020: Genitourinary Cancers Highlights – Kidney and Bladder

ASCO 2020: Checkpoint Inhibition in Metastatic Urothelial Carcinoma: Timing is Everything

ASCO 2020: JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Care vs BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma

ASCO 2020: DUTRENEO Trial: A Randomized Phase II Trial of DUrvalumab and TREmelimumab Versus Chemotherapy as a NEOadjuvant Approach to Muscle-Invasive Urothelial Bladder Cancer Patients Prospectively Selected by an Interferon-Gamma Immune Signature

ASCO 2020: Discussant: Novel Immunotherapy-Based Therapy in Metastatic Urothelial Cancers and Rare Genitourinary Malignancies

ASCO 2020: Phase II Neoadjuvant Gemcitabine and Pembrolizumab for Locally Advanced Urothelial Cancer: Interim Results from the Cisplatin-Ineligible Cohort of GU14-188

ASCO 2020: New and Updated Pivotal Trials of Single Agent and Combination Immunocheckpoint Blockers in Bladder and Kidney Cancers

ASCO 2020: Single Agent Targeted Agents vs Combinations with IO: What is the Optimal Future Therapy in Advanced Urothelial Cancer?

ASCO 2020: Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers

ASCO 2020: Emerging Biomarkers of Checkpoint Inhibitors-Based Combinations in Urothelial Cancer

ASCO 2020: Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: SWOG S1605

ASCO 2020: Association of Molecular Subtypes with Pathologic Response Interface to Studying of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle Invasive Bladder Cancer

ASCO 2020: Safety and Preliminary Efficacy of Rogaratinib in Combination with Atezolizumab in a Phase IbII Study (FORT-2) of First-Line Treatment in Cisplatin-Ineligible Patients with Locally Advanced or Metastatic UC and FGFR mRNA Overexpression

ASCO 2020: ERDAFITINIB in Locally Advanced or Metastatic Urothelial Carcinoma: Long-Term Outcomes in BLC2001

ASCO 2020: Cabozantinib in Combination with Atezolizumab in Urothelial Carcinoma Previously Treated with Platinum-Containing Chemotherapy: Results from Cohort 2 of the COSMIC-021 Study

ASCO 2020: A Phase III Randomized Study of Neoadjuvant Chemotherapy Alone or in Combination with Nivolumab ± Linrodostat Mesylate, Followed by Adjuvant Postsurgical Nivolumab ± Linrodostat, in Cisplatin-Eligible Muscle Invasive Bladder Cancer

ASCO 2020: Phase II Trial of Durvalumab plus Tremelimumab with Concurrent Radiotherapy as Bladder-Sparing Therapy in Patients with Localized Muscle Invasive Bladder Cancer: A SOGUG Study.

ASCO 2020: Study EV-103: New Randomized Cohort Testing Enfortumab Vedotin as Monotherapy or in Combination with Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer (Trial in Progress)

ASCO 2020: Pembrolizumab for the Treatment of Patients with Bacillus Calmette-Guérin Unresponsive, High-Risk Non–Muscle-Invasive Bladder Cancer: Over Two Years Follow-Up of KEYNOTE-057

ASCO 2020: Assessing the Potential Cost-Effectiveness of the Addition of Atezolizumab to First-Line Platinum Chemotherapy in Advanced Urothelial Cancer: Implications for Value-Based Pricing

1
2